Lexicon Pharmaceuticals Inc

LXRX 1.52
0.07 (4.8%)

Open: 1.44 High: 1.53 Low: 1.43

9 x 1.52 = 13.68
x $1.52 =

NASDAQ: LXRX $170 Million Small-Cap. New 52 WEEK LOW Wednesday. Health Care Sector. Biotech & Pharma Industry. 5 Year Return 88%. 1 Year Return 53%. 2020 YTD Return 63%. Negative 5 year, 1 year & YTD returns. Since Earnings 13%.

ST

External Links

Free Channels & more...

For Starters

Charts

image
image

52WL $1.43

The 52 Week Low is $1.43 set on Thu, Sep 24, 2020.

52WH $5.33

The 52 Week High is $5.33 set on Tue, Dec 10, 2019.

ATH $28.21

The All-Time High is $28.21 set on Mon, Oct 29, 2007.

52 Week Range

$1.43
$5.33
Sep 24, 2020
Dec 10, 2019

Earnings

-0.65

Earnings Per Share

0.00

Price To Earnings Ratio


Q1 Earnings for Jan, Feb & Mar

Mon, Apr 27, 2020

Since Q1 Earnings Report

LXRX 25.9%


Q2 Earnings for Apr, May & Jun

Thu, Jul 30, 2020

Since Q2 Earnings Report

LXRX 12.6%

Dividends

0.00

Dividend Yield

0.00

Dividend Rate

--

Ex-Dividend Date

--

Dividend Payment Date

--

Dividend Frequency

0

Dividend History

Profile

Lexicon Pharmaceuticals Inc trades on the NASDAQ. LXRX's market cap is 160.00 Million.

Lexicon Pharmaceuticals Inc is a biopharmaceutical company developing medicines that transform patients' lives. The company commercializes and develops drugs and drug candidates. Its drugs candidates include XERMELO (telotristat ethyl), an orally-delivered small molecule drug, in the United States for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog, or SSA, therapy in adults inadequately controlled by SSA therapy; Zynquista (sotagliflozin), an orally-delivered small molecule drug candidate, as a treatment for type 1 diabetes; sotagliflozin as a treatment for type 2 diabetes, heart failure and chronic kidney disease; and LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain.

Website

Related Channels

Account Channels

Track your portfolio and more.